Inclusion Criteria:

- Histologically/cytologically proven stage IV non-squamous NSCLC (according to IASLC
staging 7.0)

- No prior chemotherapy or therapy with systemic anti-tumor therapy (e.g., monoclonal
antibody therapy) or prior exposure to agents directed at the HER axis (e.g.
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKI), Herceptin).
Prior surgery and/or localized palliative irradiation is permitted provided that the
irradiated lesion is not the only measurable lesion. Prior adjuvant chemotherapy > 1
year ago and prior treatment with an EGFR-TKI for patients with an activating EGFR
mutation is allowed.

- Age ≥ 18 years.

- ECOG Performance Status of 0 - 2.

- Life expectancy of at least 12 weeks.

- Subjects with at least one uni-dimensional(for RECIST) measurable lesion.

- Adequate bone marrow, liver and renal function.

- Adequate non-hormonal contraception for females of childbearing potential during the
study and in the 6 months thereafter.

- Adequate contraception for male participants (or their partners) during the study and
in the 6 months thereafter.

Exclusion Criteria:

- Clinically significant (i.e. active) cardiovascular disease: congestive heart failure
>NYHA class 2; CVA or myocardial infarction < 6 months prior to study entry;
uncontrolled hypertension (blood pressure systolic > 150 mmHg and/or diastolic > 100
mmHg).

- Symptomatic hypotension.

- History of hemoptysis at least grade 2 (bright red blood of at least 2,5 ml in the
last 3 months)

- Evidence of tumor invading major blood vessels on imaging (i.e. superior vena cava or
pulmonary artery).

- History of HIV infection or chronic hepatitis B or C.

- Active clinically serious infection

- Symptomatic metastatic brain or meningeal tumors. Patients with brain metastasis may
be included the patient is treated with brain radiotherapy and asymptomatic.

- History of organ allograft.

- Patients with evidence or history of bleeding diathesis.

- Non-healing wound or ulcer.

- History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess
within 6 months of enrolment

- Anticancer chemotherapy or immunotherapy during the study or within 4 weeks of study
entry

- Radiotherapy within 4 weeks of start of study drug. Palliative radiotherapy for bone
lesions is allowed > 14 days of start of chemotherapy. Major surgery within 4 weeks
of start of study.

- Use of vasodilators (including 5-phosphodiesterase inhibitors, calcium antagonists or
nitrates)

- Autologous bone marrow transplant or stem cell rescue within 4 months of study

- Investigational drug therapy outside of this trial during or within 4 weeks of study
entry

- Pregnancy or lactation.